亞盛醫藥(06855.HK)發布奧瑞巴替尼兩項關鍵性臨床結果
亞盛醫藥-B(06855.HK)公布,公司在研原創1類新藥HQP1351(擬定中文通用名:奧瑞巴替尼)的兩項關鍵性註冊II期臨床的積極研究結果,已在第62屆美國血液學會(ASH)年會上以口頭報告的形式公佈,數據令人鼓舞。
這兩項研究數據顯示,HQP1351在伴有T315I突變的TKI耐藥的CML-CP及CML-AP患者中均具有良好的療效及耐受性,且隨著治療時間的延長,緩解率和緩解深度會進一步增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.